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use#LAAPhthalates are a class of synthetic compounds
used widely in polyvinyl chloride plastics,
in cosmetics, and in building materials.
Biomonitoring data suggest that > 75% of the
U.S. population is exposed to phthalates,
including di-(2-ethylhexyl) phthalate (DEHP),
di-n-butyl phthalate (DnBP), di-isobutyl
phthalate (DiBP), butylbenzyl phthalate
(BBzP), and diethyl phthalate (DEP) (Silva
et al. 2004a). When urinary concentrations of
secondary metabolites of DEHP [e.g., mono-
(2-ethyl-5-oxohexyl) phthalate (MEOHP),
mono-(2-ethyl-5-hydroxyhexyl) phthalate
(MEHHP)] are measured, this estimate
increases to 95% (Kato et al. 2004). It is
assumed that the general population is exposed
to some phthalates mainly through ingestion
of foods contaminated during processing and
packaging (Schettler 2006; Wormuth et al.
2006). Dermal contact with products contain-
ing phthalates, inhalation of indoor air, and
inhalation or ingestion of household dust also
contribute to widespread exposures.
Once a pregnant woman is exposed,
phthalates can cross the placenta and enter
fetal circulation (Mose et al. 2007). Phthalates
have been detected in physiologically relevant
compartments within pregnant women and
the developing fetus, such as maternal urine
(Adibi et al. 2003; Swan et al. 2005), cord
blood (Latini et al. 2003), meconium (Kato
et al. 2006), placenta (Mose et al. 2007), and
amniotic ﬂuid (Silva et al. 2004b). 
Previous studies on the reproducibility of
phthalate metabolite concentrations in urine
samples among nonpregnant individuals have
shown a wide range of estimates of within-
person variability (Fromme et al. 2007; Hauser
et al. 2004; Hoppin et al. 2002; Teitelbaum
et al. 2007), leading to concerns regarding the
approach of relying on a single sample to
characterize exposure. In addition, these stud-
ies may not accurately represent what happens
during pregnancy when a woman’s physiology
is dramatically altered.
The primary aim of the current study was
a) to use biomarkers of exposure (i.e., metabo-
lites measured in urine) to evaluate variability
in phthalate concentrations in pregnant
women; and b) to evaluate variability in meas-
ures of phthalates in their external environ-
ment (i.e., indoor air). As a secondary aim, we
evaluated correlations between phthalate
metabolite concentrations measured in mater-
nal and newborn urine. Finally, we evaluated
the correlation between phthalate levels in
personal/indoor air and urinary metabolite
concentrations.
Methods
Study population. Subjects were recruited
into the Columbia Center for Children’s
Environmental Health (CCCEH) cohort at
prenatal clinics located in three New York
City neighborhoods in Northern Manhattan
and the South Bronx. To be eligible for
enrollment, subjects had to reside in the study
area for at least 1 year, receive their ﬁrst prena-
tal visit by the 20th week of pregnancy, and
be free of diabetes, hypertension, and known
HIV and drug or alcohol abuse (Perera et al.
2006; Whyatt et al. 2003). A variability study
using a repeated-measures design was carried
out in a subset of 102 women from the 
full CCCEH cohort (Whyatt et al. 2007).
Variability study subjects were not employed
outside the home. At the time of enrollment,
all subjects completed a prenatal question-
naire. Information was also abstracted from
prenatal and delivery medical records. The
CCCEH study and the substudies were
approved by the institutional review boards of
Columbia University and the Centers for
Disease Control and Prevention (CDC) and
the Harvard School of Public Health Human
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BACKGROUND: Although urinary concentrations of phthalate metabolites are frequently used as
biomarkers in epidemiologic studies, variability during pregnancy has not been characterized.
METHODS: We measured phthalate metabolite concentrations in spot urine samples collected from
246 pregnant Dominican and African-American women. Twenty-eight women had repeat urine
samples collected over a 6-week period. We also analyzed 48-hr personal air samples (n =9 6
women) and repeated indoor air samples (n = 32 homes) for ﬁve phthalate diesters. Mixed-effects
models were ﬁt to evaluate reproducibility via intraclass correlation coefﬁcients (ICC). We evalu-
ated the sensitivity and specificity of using a single specimen versus repeat samples to classify a
woman’s exposure in the low or high category.
RESULTS: Phthalates were detected in 85–100% of air and urine samples. ICCs for the unadjusted
urinary metabolite concentrations ranged from 0.30 for mono-ethyl phthalate to 0.66 for
monobenzyl phthalate. For indoor air, ICCs ranged from 0.48 [di-2-ethylhexyl phthalate (DEHP)]
to 0.83 [butylbenzyl phthalate (BBzP)]. Air levels of phthalate diesters correlated with their respec-
tive urinary metabolite concentrations for BBzP (r = 0.71), di-isobutyl phthalate (r = 0.44), and
diethyl phthalate (DEP; r = 0.39). In women sampled late in pregnancy, speciﬁc gravity appeared
to be more effective than creatinine in adjusting for urine dilution.
CONCLUSIONS: Urinary concentrations of DEP and DEHP metabolites in pregnant women showed
lower reproducibility than metabolites for di-n-butyl phthalate and BBzP. A single indoor air sam-
ple may be sufﬁcient to characterize phthalate exposure in the home, whereas urinary phthalate bio-
markers should be sampled longitudinally during pregnancy to minimize exposure misclassiﬁcation.
KEY WORDS: creatinine, indoor air, personal air, phthalates, pregnancy, specific gravity, urinary
metabolites, variability. Environ Health Perspect 116:467–473 (2008). doi:10.1289/ehp.10749
available via http://dx.doi.org/ [Online 15 January 2008]
ResearchSubjects Committee. Written informed con-
sent was obtained from all study subjects.
Phthalate measures. Sampling design.
During the third trimester of pregnancy,
women (n = 96) were asked to wear a small
backpack holding a personal ambient air
monitor during the daytime hours for 2 con-
secutive days and to place the monitor near
their beds at night. Over this period, the per-
sonal air sampling pumps operated continu-
ously at 4 L/min, collecting particles
≤ 2.5 μm in diameter on a precleaned quartz
microfiber filter and collecting semivolatile
vapors and aerosols on a polyurethane foam
(PUF) cartridge backup. At the end of the
48-hr monitoring period, all women gave a
spot urine sample, which we refer to as 48-hr
monitoring. Urine samples were also collected
in the hospital from a subset of mothers
(n = 16) and from their newborns (n = 19)
1 day after delivery. The newborn urine sam-
ples were collected by attaching urine-collec-
tion bags to the babies.
The variability study was carried out on a
subset of subjects (n = 32) who completed the
48-hr personal monitoring. Indoor air moni-
tors placed in the women’s apartments ran
continuously for 2 weeks. As previously
described by Whyatt et al. (2007), monitoring
was conducted using a pump with a 0.5 L/min
ﬂow-rate attached to a similar PUF sampler. At
the end of each 2-week period, the air sampler
and battery were replaced and the subject gave
a spot urine sample. The indoor air sampling
began at 31.0 ± 1.7 (mean ± SD) weeks of ges-
tation, and the urine collection began at
33.0 ± 1.7 weeks of gestation. The indoor air
monitoring and urine collection continued
until the women went into labor and will be
referred to as the 6-week monitoring. When
possible, we combined the 48-hr and 6-week
monitoring periods to give a total of 8 weeks of
observation.
Urinary metabolite measures. All urine
samples were analyzed at the National Center
for Environmental Health of the CDC for four
phthalate metabolites: mono-ethyl phthalate
(MEP), mono-n-butyl phthalate (MnBP),
mono-benzyl phthalate (MBzP), and mono-2-
ethylhexyl phthalate (MEHP). As analytical
methods and knowledge of phthalate metabo-
lism improved, the panel of urinary metabolites
increased, and most participants also had mea-
sures for ﬁve additional metabolites: MEOHP,
MEHHP, mono-2-ethyl-5-carboxypentyl
phthalate (MECPP), mono-isobutyl phthalate
(MiBP), and mono-3-carboxypropyl phthalate
(MCPP). The 48-hr study urine samples were
analyzed in four separate batches during
2001–2006. The variability study urine samples
were all analyzed in the 2006 batch.
The analytical approach for measuring uri-
nary phthalate metabolites involved enzymatic
deconjugation of the metabolites from their
glucuronidated form, solid-phase extraction,
separation with high-performance liquid chro-
matography, and detection by isotope-dilution
tandem mass spectrometry (Blount et al.
2000; Kato et al. 2005; Silva et al. 2003; Silva
et al. 2004c). To monitor for accuracy and
precision, each analytical run included—
together with unknown samples—calibration
standards, reagent blanks, and quality control
materials of high and low concentrations. The
limits of detection (LODs), which varied
slightly depending on the method used, were
in the low nanogram-per-milliliter range.
Concentrations < LOD were set to one-half
the LOD for calculations. Creatinine concen-
tration was measured using an enzymatic reac-
tion on a Roche Hitachi 912 chemistry analyzer
(Roche Hitachi, Basel, Switzerland). Metabolite
concentrations were creatinine-adjusted to give
micrograms per gram creatinine. As an alterna-
tive to creatinine, speciﬁc gravity was measured
in the variability study samples. Methods for
speciﬁc gravity measurement are described else-
where (Hauser et al. 2004).
Personal and indoor air analysis. The per-
sonal and indoor air samples were analyzed at
the Southwest Research Institute for ﬁve phtha-
lates: DEHP, DnBP, BBzP, DiBP, and DEP.
Methods are described elsewhere (Rudel et al.
2003). After being stored and shipped at –4°C,
the PUF and ﬁlter were soxhlet-extracted with
6% diethyl ether in hexane and concentrated to
10 mL, of which an aliquot was used for phtha-
late analysis. Gas chromatography (GC)/mass
spectrometry was performed using an Agilent
6890 GC equipped with an Agilent 5973 Mass
Selective Detector (Agilent Technologies Inc.,
Santa Clara CA) in selected ion monitoring
mode. Two deuterated phthalates were used as
internal standards for quantitation.
Phthalates were measured in blank PUF
cartridges to estimate levels of potential phtha-
late contamination in the sampling and analy-
sis process. If phthalate amounts in the blanks
were > LOD, the samples were flagged. To
obtain the concentration of phthalate per
cubic meter of air, we divided the extract value
by the total volume (in cubic meters) of air
pulled through the pump during the sample
period. Although mean phthalate levels in per-
sonal air samples were at least an order of
magnitude higher than in air matrix blanks, a
few air sample amounts of BBzP and DEHP
were lower than the maximum air matrix
blank amount for that phthalate.
Statistical analysis. Phthalate diester levels
in air (micrograms per cubic meter) and
phthalate metabolites in urine (nanograms per
milliliter) are reported as percentiles, and as
geometric means with corresponding 95%
confidence intervals (CIs). %MEHP3, the
ratio of MEHP to three DEHP metabolites
(MEHP, MEOHP, and MEHHP), was used
as a phenotypic marker of DEHP metabolism
(Hauser et al. 2007). %MEHP4 is the ratio of
MEHP to four DEHP metabolites (MEHP,
MEOHP, MEHHP, and MECPP). Using
geometric means and 95% CIs, we compared
concentrations measured in the CCCEH
study population with those measured in the
National Health and Nutrition Evaluation
Survey (NHANES) [CDC/National Center
for Health Statistics (NCHS) 1999–2000,
2001–2002]. We used publicly accessible uri-
nary concentration data from NHANES
1999–2000 and 2001–2002 for eight metabo-
lites to estimate the mean concentrations in
U.S. females between the ages of 18 and
Adibi et al.
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Table 1. Demographic characteristics of CCCEH subjects with phthalate measurements.
Full study 48-hr monitoring 6-week monitoring
Characteristic (n = 246) (n = 96) (n = 32)
Age [years (mean ± SD)]  25.6 ± 4.6a  25.1 ± 4.3b  26.0 ± 5.0
Gestational age [weeks (mean ± SD)] 39.2 ± 1.9c  39.3 ± 1.6d  39.2 ± 3.1e 
Dates of enrollment [years (range)] 1999–2005 2000–2005 2002–2004
Years of education
Missing 3 (1) 3 (3) 0
< High school 91 (37) 38 (41) 17 (53)
High school or GED 89 (37) 33 (36) 9 (28)
> High school 63 (26) 22 (23) 6 (19)
Ethnicity
Missing 4 (2) 3 (3) 0
Dominican/Dominican American 179 (74) 75 (81) 25 (78)
African American 63 (26) 18 (19) 7 (22)
Marital status
Missing 4 (2) 3 (3) 0
Never married 152 (62) 61 (66) 21 (66)
Married 76 (31) 30 (32) 8 (25)
Separated, widowed, or divorced 14 (6) 2 (2) 3 (9)
Household income (US$)
Missing 31 (13) 14 (15) 6 (19)
< 10,000 94 (44) 37 (45) 11 (42)
10,000–30,000 96 (47) 35 (43) 14 (54)
> 30,000 25 (9) 10 (12) 1 (4)
GED, General Educational Development. Values are no. (%) except where indicated. 
aFour missing. bThree missing. cThirty-three missing. dFive missing. eTwo missing.40 years. Additionally, we calculated the geo-
metric mean concentration and 95% CI for
U.S. pregnant females (n = 209 for MEHP,
MEP, and MBzP; n = 104 for MEOHP,
MEHHP, MnBP, MiBP, and MCPP). Given
that the NHANES sample was nonrandom,
we used the recommended methods to cor-
rectly estimate variances (NCHS 2007).
To evaluate correlations between untrans-
formed concentrations of phthalates in urine
(metabolites), indoor air, and personal air, we
used Spearman correlations with a Fisher Z
transformation to estimate 95% CIs. In cases
of multiple samples per subject, we used a
geometric mean to summarize all values for
that subject. When modeling variability, we
applied a logarithmic transformation to the
air and urine phthalate measurements to bet-
ter approximate a normal distribution.
Mixed-effects models were ﬁt to estimate the
temporal variability in phthalate concentra-
tions and to estimate the intraclass correlation
coefficients (ICCs). We chose the most
appropriate covariance structure by compar-
ing Akaike information criterion (AIC) values
between a covariance that assumes a constant
correlation between any pair of measurements
made on the same subject versus a ﬁrst-order
autoregressive structure, which assumes that
measurements on the same subject taken
closer in time are more highly correlated than
those taken further apart. An ICC, the ratio
of between-subject variance to total variance,
is a measure of reproducibility of a biomarker
sampled from the same group of individuals
over time, and ranges from 0 (no repro-
ducibility) to 1 (perfect reproducibility; i.e.,
100% of the variance is due to between-subject
differences) (Rosner 2000). 
The sensitivity and specificity of using a
single urine sample per woman to classify her
exposure to phthalates as low or high, com-
pared with using three to five samples per
subject, was estimated by randomly selecting
a single sample from among each woman’s
repeated samples collected over all 8 weeks.
The metabolite concentrations (nanograms
per milliliter) for the single sample were com-
pared to the NHANES geometric mean
(nanograms per milliliter) for that metabolite
calculated for U.S. women of reproductive
age and classiﬁed as below (low) or above the
geometric mean (high). The geometric mean
of a woman’s repeat samples was considered
to reflect her “true” exposure and was simi-
larly classified as low or high relative to the
NHANES geometric mean for that metabo-
lite. For each woman, the single selected sam-
ple was compared to the geometric mean of
all her remaining samples (excluding the
selected sample) in terms of low versus high
exposure, and the sensitivity and specificity
were calculated. This process was repeated
1,000 times, generating 1,000 estimates of
sensitivity and specificity. We report the
empirical estimates of the median sensitivity
and specificity and empirical CIs for each
metabolite. We used SAS, version 9.1 (SAS
Institute Inc., Cary, NC) for all statistical
analyses. We used Microsoft Excel 2003 SP2
(Microsoft Corporation, Redmond, WA) to
generate graphics.
Results
Background characteristics of the study sample.
The demographics of our study sample, shown
in Table 1, reflect the demographics of the
overall CCCEH cohort. The mean age was
25.6 years; 74% of subjects were Dominican;
74% had an education at or below high school
level; and 62% were never married. The sub-
jects in the variability study were similar in age
and marital status and were more likely to have
a lower educational level (81% had a high
school education or less).
Urinary phthalate metabolites in pregnant
women and newborns. The distributions of the
nine urinary phthalate metabolite concentra-
tions among pregnant women are summarized
in Table 2. All urinary metabolites were
detected in the pregnant women at 100% fre-
quency, except for MEHP (85%) and MCPP
(89%). Geometric mean concentrations of two
urinary metabolites (MnBP, MiBP) were
higher in the CCCEH participants than in the
NHANES females of reproductive age
(18–40 years) (Table 2). In pregnant women,
the geometric means were signiﬁcantly higher
in the CCCEH subjects than in the NHANES
participants for MnBP (37.5 vs. 19.6 ng/mL)
and for MiBP (9.5 vs. 2.5 ng/mL). On aver-
age, the CCCEH subjects had a signiﬁcantly
lower %MEHP than the NHANES pregnant
females (11% vs. 17%).
Comparisons between concentrations in
mothers and their newborns are illustrated in
Figure 1. In the newborns, the detection fre-
quencies were 42% (MEHP), 68% (MCPP,
MEOHP, and MEHHP), 89% (MBzP and
MnBP), 99% (MEP), and 100% (MECPP).
Most metabolite concentrations in the new-
borns were consistently lower than maternal
concentrations based on the geometric mean.
However, the median concentration of
MECPP was higher in the newborns than in
the mothers (56.9 vs. 36.1 ng/mL).
We found no correlation between phtha-
late metabolite concentrations measured in
urine samples collected from mothers and
Phthalate exposure and variability in pregnancy
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Table 2. Urinary phthalate metabolite concentrations (ng/mL) in Dominican-American and African-American pregnant women living in New York City, and
comparison with a U.S. population–based sample (NHANES).
Phthalate Percent Percentile CCCEH (n = 246) NHANESa 
Phthalate diester metabolite No. > LOD 5th 25th 50th 75th 95th [GM (95% CI)] [GM (95% CI)]
DEP MEP 246 100 36.8 103 202 481 2,753 232 (199–272) 235 (200–277)
DEHP MEHP 246 85 0.5 2.2 4.8 13.6 46.8 4.8 (4.0–5.8) 4.5 (4.0–5.0)
MEOHP 221 100 2.8 9.4 17.5 33.6 107.6 18.2 (15.6–21.3) 13.8 (10.4–18.3)
MEHHP 221 100 2.5 10.4 19.9 43.4 149.6 20.2 (17.2–23.6) 19.8 (14.9–26.2)
MECPP 220 100 6.2 20.5 37.1 81.2 232.2 38.3 (33.3–44.0) NA
%MEHP3 221 NAb  3% 7% 12% 18% 28% 11% (10–12) 13% (11–14)
%MEHP4 220 NAb  1% 4% 7% 10% 17% 6% (5–6) NA
DnBP/DiBP MnBP 246 100 7.3 23.0 35.5 70.1 174.9 37.5 (33.3–42.2) 21.5 (17.1–27.2)
MiBP 221 100 1.9 5.4 10.2 17.1 36.1 9.5 (8.4–10.8) 3.0 (2.5–3.5)
DnOP/DBP MCPP 220 89 0.3 1.1 2.0 3.8 8.0 1.9 (1.6–2.2) 2.6 (2.1–3.3)
BBzP MBzP 246 100 1.7 8.0 17.2 43.6 146.8 17.5 (14.8–20.7) 16.5 (14.2–19.2)
DnOP, di-n-octyl phthalate; GM, geometric mean; NA, not applicable. 
aFemales 18–40 years of age; n = 853 for metabolites measured in 1999–2002 (MEP, MEHP, MBzP); n = 437 for metabolites measured in 2001–2002 only (MEOHP, MEHHP, MnBP, MiBP,
MCPP). bValues < LOD were set to 0.5 × LOD and used in %MEHP calculation. 
Figure 1. Urinary proﬁle of phthalate metabolite con-
centrations in pregnant women and their newborns.
Error bars represent upper bounds of 95% CIs.
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CCCEH mothers (n = 19)
CCCEH newborns (n = 19)their newborns approximately 1 day after
delivery. For three metabolites, there was a
suggestive inverse correlation between the
geometric mean of 19 mothers’ samples (two
to five urine samples collected over 8 weeks
before delivery) with their newborns’ urinary
metabolites measured 1 day after delivery
(MEHP, r = –0.31, p = 0.19; MCPP,
r = –0.39, p = 0.09; MBzP, r = –0.29,
p = 0.22) (Figure 2).
Phthalate measurements in personal and
indoor air. Concentrations of five phthalate
diesters measured in personal air are summa-
rized in Table 3. All five phthalates were
detected at 100% frequency in the air samples.
The geometric mean values were higher for
personal air compared with indoor air. There
was overlap in the CIs for all phthalates except
DEHP, which was significantly higher by
2-fold in the personal air samples. When we
limited the analysis to subjects who had both a
personal air and indoor air sample (n = 27),
there was a positive correlation between 48-hr
personal air and the average indoor air levels
over the 8 weeks of sampling for all ﬁve phtha-
late diesters, estimated as 0.54 for DnBP
(p = 0.002), 0.67 for BBzP (p < 0.0001), 0.51
for DEP (p = 0.005), 0.31 for DiBP (p = 0.11),
and 0.25 for DEHP (p = 0.21) (Figure 2).
Variability study: urinary phthalate
metabolites. For the urine variability analysis,
we excluded 3 women with only one urine
sample and 1 woman with missing urinary cre-
atinine values. Of the remaining 28 subjects,
12 women had two samples and 16 women
had three or four samples. We were limited to
samples collected over the 6-week monitoring
period because of missing data on urinary dilu-
tion for the 48-hr monitoring sample. Onset of
labor was the primary reason that urine sam-
ples were unavailable for some subjects at
weeks 4 and 6, which correspond approxi-
mately to weeks 37 and 39 of gestation.
The ICCs for the nine metabolites in urine
ranged from 0.30 to 0.66 without adjustment
for creatinine, and decreased to 0.21–0.65 with
creatinine adjustment (Table 4). MEP and the
metabolites of DEHP had the lowest repro-
ducibility, with ICCs ranging from 0.30 to
0.36. %MEHP was a stable measure within a
woman during 6 weeks in late pregnancy, with
an ICC of 0.64 for %MEHP3 and 0.60 for
%MEHP4. We also compared ICCs calcu-
lated with adjustment for speciﬁc gravity in a
subset of 22 subjects sampled over the same
time period. For the DEHP and DEP metabo-
lites, the specific gravity ICC estimates were
higher than those for creatinine-adjusted
metabolites but lower than the unadjusted esti-
mates. For the DnBP and BBzP metabolites,
the speciﬁc gravity estimates were higher than
both the unadjusted and the creatinine-
adjusted estimates (data not shown). The
covariance structure that assumes a constant
correlation between any two measurements on
a single subject yielded a better model fit
(lower AIC value) and was applied in all
mixed-effects models. We did not detect signif-
icant temporal trends in metabolite levels over
the 6-week period.
We evaluated the sensitivity and speciﬁcity
of characterizing exposure based on a single
sample compared with all available samples
using women who had three to ﬁve repeated
urine samples over 8 weeks (n = 26) (Table 5).
The probability of correctly classifying a
woman as having high exposure based on a sin-
gle randomly selected urine sample, if she truly
was in a high exposure category based on all
her urine samples (i.e., sensitivity), ranged
from 0.50 (MiBP) to 0.74 (MCPP). The prob-
ability ranged from 0.43 (MEP) to 0.95
(MiBP) of correctly classifying a woman as
having low exposure if she truly was in a low-
exposure category (i.e., speciﬁcity).
Variability study: phthalate measures in
air. For the 32 women in the 6-week moni-
toring study, 6 provided two indoor air sam-
ples each, 11 women provided three samples
each, and 15 women provided four samples
each. Within a woman’s home, the indoor air
phthalate levels were more stable over time
than were her urinary phthalates. The ICCs
were 0.61 for DEP, 0.54 for DiBP, 0.59 for
DnBP, 0.48 for DEHP, and 0.83 for BBzP.
Association between phthalate levels
measured in air and urine. We calculated
estimated Spearman correlation coefficients
between phthalate levels in paired indoor air
and urine samples collected over 6 weeks in
late pregnancy (n = 27). These correlations
were compared to paired 48-hr personal air
and urine samples (n = 62) (Figure 2). After
adjustment for speciﬁc gravity, which tended
to yield stronger correlations than after
adjustment for creatinine, we saw a signifi-
cant association between BBzP in indoor air
and MBzP in urine (r = 0.71, p < 0.0001)
and between BBzP in personal air and MBzP
in urine (r = 0.48, p < 0.0001). The correla-
tion between DiBP in indoor air and MiBP
in urine was weaker (r = 0.44, p = 0.02).
There were significant associations between
DEP in indoor air and MEP in urine
(r = 0.39, p = 0.04) and DEP in personal air
and MEP in urine (r = 0.27, p = 0.04). No
associations were detected between DEHP or
DnBP and their respective metabolites.
Adibi et al.
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Figure 2. Summary of Spearman coefﬁcients of correlation between phthalate concentrations measured in
environmental and biologic matrices.
aUnadjusted for urinary dilution (data not available). bAdjusted for speciﬁc gravity. *p < 0.20. **p < 0.05.
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Table 3. Phthalate concentrations (µg/m3) in 48-hr personal air samples of pregnant Dominican-American and African-American women living in New York City
compared with geometric means of indoor air.
Percent  Percentile Geometric mean (95% CI)
Phthalate diester No. > LOD 5th 25th 50th 75th 95th Personal air Indoor air (n = 32)
DEHP 96 100 0.07 0.11  0.19 0.29 0.49 0.18 (0.16–0.21) 0.09 (0.08–0.10)
DnBP 96 100 0.19 0.32 0.48 0.63 1.04 0.45 (0.41–0.51) 0.38 (0.33–0.45)
BBzP 96 100 0.01 0.02 0.04 0.13 0.27 0.05 (0.04–0.06) 0.03 (0.02–0.04)
DiBP 96 100 0.17 0.33 0.50 0.77 1.43 0.50 (0.44–0.57) 0.45 (0.38–0.53)
DEP 96 100 0.84 1.47 2.33 3.36 5.06 2.15 (1.92–2.41) 1.66 (1.38–2.00)Discussion
In a small sample of pregnant women, the
reproducibility of urinary phthalate metabolite
concentrations measured over a period of
6–8 weeks late in pregnancy was low to moder-
ate. Reproducibility can be ranked in the fol-
lowing order: MEP (0.30), DEHP metabolites
(mean ICC = 0.35), DnBP metabolites (mean
ICC = 0.58), %MEHP3 and %MEHP4 (mean
ICC = 0.62), and MBzP (0.64). The proposed
measure of interindividual differences in metab-
olism and excretion (%MEHP) was more sta-
ble over time within a pregnant woman than
the corresponding DEHP metabolites by
approximately 2-fold. The CCCEH subjects
had signiﬁcantly higher mean urinary concen-
trations of MiBP (3-fold) and MnBP (43%)
than U.S. females of reproductive age.
An ICC of 0.40 has been proposed as a
cutoff for sufficient reproducibility in a bio-
marker to justify its use in an epidemiologic
analysis (Rosner 2000) and has been cited in
previous reports on the reproducibility of
phthalate urinary metabolites (Hauser et al.
2006; Rosner 2000; Teitelbaum et al. 2007).
However, this cutoff may be arbitrary and
could still allow substantial misclassification
that would bias an effect estimate toward the
null. According to a simulation study con-
ducted by de Klerk (1989), an exposure vari-
able with an ICC of 0.42 would be associated
with 32% attenuation in the estimated rela-
tive risk due to exposure misclassification,
which is clearly undesirable. We observed
ICCs < 0.50 for MEP and DEHP metabo-
lites, suggesting that within-subject variability
may be of greater magnitude than between-
subject variability. Thus, studies relying on a
single sample per subject may have unreliable
effect estimates, and ideally we would recom-
mend using repeated measures taken over the
entire course of the pregnancy.
Within-subject variability in phthalate
concentrations measured in indoor air during
the same 6-week period was lower than that in
urine, suggesting that exposures to phthalates
are relatively constant within the home. Of
the phthalates measured, DEHP has the low-
est volatility (Wormuth et al. 2006), which
might explain its lower concentrations in
indoor air. Other studies have shown air con-
centrations of DEHP to be low, whereas
household dust concentrations are consistently
high (Bornehag et al. 2004; Rudel et al.
2003). Poor reproducibility for DEHP might
mean the air concentrations are dependent on
dust concentrations at the time of sampling,
which could be associated with intermittent
activities such as cleaning and moving furni-
ture. BBzP was the most stable phthalate
measured in indoor air.
To date, four separate studies have
reported estimates of reproducibility of uri-
nary phthalate metabolites (Fromme et al.
2007; Hauser et al. 2004; Hoppin et al. 2002;
Teitelbaum et al. 2007). ICC estimates vary
considerably, given the differences in study
design, exposure patterns, age, and underlying
physiology of subjects. We compared the rank
orders of the estimates between studies.
Hoppin et al. (2002), measured variability
over a short period of 2 days and found all
metabolites to be highly reproducible, and
Hauser et al. (2004) found MEP to be the
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Table 4. Variance in log-transformed urinary phthalate metabolite concentrations in pregnant women
sampled over 6 weeks in late pregnancy (n = 28; 2–4 repeats).
Log-transformed concentration
Phthalate diester Phthalate metabolite Unadjusted Creatinine adjusted
DEHP MEHP
ICC 0.35 0.25
Subject (SE) 0.79 (0.39) 0.53 (0.34)
Residual (SE) 1.46 (0.31) 1.56 (0.34)
MEOHP
ICC 0.34 0.22
Subject (SE) 0.58 (0.28) 0.36 (0.25)
Residual (SE) 1.14 (0.24) 1.26 (0.27)
MEHHP
ICC 0.36 0.23
Subject (SE) 0.69 (0.33) 0.41 (0.28)
Residual (SE) 1.23 (0.26) 1.41 (0.30)
MECPP
ICC 0.33 0.21
Subject (SE) 0.53 (0.27) 0.31 (0.23)
Residual (SE) 1.08 (0.23) 1.16 (0.25)
%MEHP3
ICC 0.64 NAa
Subject (SE) 0.39 (0.13)
Residual (SE) 0.22 (0.05)
%MEHP4
ICC 0.60 NAa
Subject (SE) 0.45 (0.16)
Residual (SE) 0.29 (0.06)
DnBP/DiBP MnBP
ICC 0.62 0.55
Subject (SE) 0.90 (0.32) 0.63 (0.23)
Residual (SE) 0.56 (0.12) 0.50 (0.11)
MiBP
ICC 0.54 0.48
Subject (SE) 1.02 (0.40) 0.73 (0.31)
Residual (SE) 0.85 (0.19) 0.80 (0.18)
MCPP
ICC 0.44* 0.41*
Subject (SE) 0.56 (0.25) 0.48 (0.22)
Residual (SE) 0.70 (0.15) 0.69 (0.15)
BBzP MBzP
ICC 0.66 0.65
Subject (SE) 1.76 (0.60) 1.48 (0.52)
Residual (SE) 0.91 (0.20) 0.79 (0.17)
DEP MEP
ICC 0.30* 0.21
Subject (SE) 0.56 (0.34) 0.36 (0.29)
Residual (SE) 1.33 (0.29) 1.31 (0.29)
NA, not applicable. 
a%MEHP is not changed by creatinine adjustment. *p ≤ 0.05 for type 3 test of differences between ≥ 2 samples over
4–6 weeks. 
Table 5. Sensitivity and specificity (ng/mL) of high/low phthalate exposure classification in a pregnant
woman based on a single urine sample compared with 3–5 samples per subject.
Median (95% CI)
Phthalate diester Phthalate metabolite  Speciﬁcity Sensitivity
DEHP MEHP 0.80 (0.67–0.93) 0.64 (0.38–0.89)
MEOHP 0.63 (0.44–0.86) 0.60 (0.40–0.88)
MEHHP 0.50 (0.29–0.70) 0.62 (0.47–0.83)
DnBP/DiBP MnBP 0.88 (0.72–1.00) 0.67 (0.44–0.89)
MCPP 0.56 (0.29–0.83) 0.74 (0.60–0.89)
MiBP 0.95 (0.87–1.00) 0.50 (0.25–1.00)
BBzP MBzP 0.73 (0.57–0.92) 0.73 (0.54–0.89)
DEP MEP 0.43 (0.18–0.71) 0.72 (0.56–0.88)most reproducible, thus suggesting a different
exposure pattern. In contrast, in the present
study, we saw a trend by which the DnBP
metabolites and the BBzP metabolites were
consistently the most reproducible and the
DEHP and DEP metabolites were the least
reproducible within a person over time. This
comparison reinforces the importance of char-
acterizing inter- and intrasubject variability for
different populations.
Depending on the research question,
investigators may choose to group subjects by
tertiles, quintiles, or even into low- and high-
exposure categories. When relying on a single
urine sample, this may reduce exposure mis-
classification because of within-subject vari-
ability. In our analysis of sensitivity and
specificity, we found a similar trend as with
the ICCs. DEP (0.43) and DEHP metabo-
lites averaged (0.64) had the lowest speci-
ficity, whereas BBzP (0.73) and DnBP
metabolites averaged (0.80) had the highest.
The observation that creatinine adjust-
ment actually increased within-person vari-
ability and reduced reproducibility in urinary
concentrations of phthalate metabolites was
unexpected and inconsistent with other stud-
ies (Fromme et al. 2007; Hoppin et al. 2002).
This difference may be explained by physio-
logic changes in late pregnancy that could
alter creatinine production and/or excretion.
Creatinine excretion on average increases by
30% in a pregnant woman, as does kidney
size (Williams 2005). During the third
trimester, however, there is a precipitous drop
in the renal blood flow rate that could alter
creatinine excretion (Williams 2005). For
these reasons, creatinine may vary indepen-
dently of phthalate excretion late in preg-
nancy. We compared variability in creatinine
and specific gravity for 24 women who pro-
vided two to four repeat urine samples over
4–6 weeks. We found that creatinine had a
lower ICC of 0.36 compared to speciﬁc grav-
ity, which had an ICC of 0.58. Speciﬁc grav-
ity, which is a measure of urine turbidity, has
been proposed as a more appropriate method
for adjusting phthalate concentrations
(Hauser et al. 2004). In the case of pregnant
women, we also propose that alternative
methods be explored.
The presence of MECPP in 100% of the
newborn samples and the fact that it was at the
highest concentration suggests that the new-
borns were exposed to DEHP in utero, during
the labor and delivery process, and/or within
the ﬁrst 24 hr after delivery. MECPP, which is
largely in its free, unglucuronidated form in
urine and has the longest elimination half-life
of the DEHP metabolites examined, may be
an appropriate biomarker of cumulative
DEHP dose (Koch et al. 2006; Silva et al.
2006). The inverse correlations and higher
maternal versus newborn concentrations that
we observed for some of the metabolites may
indicate that placental transporters are involved
in actively shuttling phthalate metabolites out
of fetal circulation, as it has already been estab-
lished that they diffuse passively into fetal cir-
culation in rodents (Saillenfait et al. 1998;
Singh et al. 1975). However, we are not aware
of data to support this hypothesis.
The correlations between phthalates in
indoor air and urine partly conﬁrmed our pre-
vious report (Adibi et al. 2003). Differences
between that study and the present one may
be due to differences in statistical power, sam-
pling variability, confounding, temporal
trends in exposure, and possibly batch effects
in the laboratory analyses. Air concentrations
of BBzP, which is commonly used in artiﬁcial
rubbers, spray paints, and furniture coverings,
were correlated signiﬁcantly with urinary con-
centrations of MBzP and at the highest mag-
nitude of those measured. Even though we
had repeat measures of both indoor air and
urine increasing our power to detect an associ-
ation, we were still limited by a small sample
size of 27.
Conclusion 
In the present study, we found urinary phtha-
late metabolite concentrations to be moder-
ately to highly variable in a small sample of
pregnant women sampled over 6 weeks late in
pregnancy, whereas indoor air concentrations
were more stable during the same period. The
variability that we observed could be in part
due to changes in exposure and/or physiologic
changes in pregnancy, which alter metabolism
and excretion of phthalates. As proposed in
previous studies (Hauser et al. 2007),
%MEHP proved to be a stable measure within
a person over time and should be explored as a
measure of phenotypic differences in metabo-
lism and excretion. Our ﬁndings also suggest
that creatinine adjustment might not be the
optimal method of urinary dilution adjustment
for subjects sampled late in pregnancy. Future
research should be directed at increasing the
number of urine samples collected and the
number of intervals between samples over the
duration of the pregnancy to reduce misclassiﬁ-
cation in measures of phthalate exposure. This
will strengthen our ability to evaluate risks to
the mother and the fetus associated with pre-
natal phthalate exposures.
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